Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial

Editorial

S Evans et al. BMJ. 2001.

. 2001 Mar 10;322(7286):569-70.

doi: 10.1136/bmj.322.7286.569.

No abstract available

Comment in

Responsibilities of sponsors are limited in premature discontinuation of trials.
Ashcroft R. Ashcroft R. BMJ. 2001 Jul 7;323(7303):53. BMJ. 2001. PMID: 11464837 Free PMC article. No abstract available.

Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.
Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, Leitersdorf E, Luc G, Masana L, Moulin P, Passa P, Pouchain D, Siest G. Lièvre M, et al. BMJ. 2001 Mar 10;322(7286):603-5. doi: 10.1136/bmj.322.7286.603. BMJ. 2001. PMID: 11238162 Free PMC article. Review. No abstract available.

1. International Conference on Harmonisation. ICH tripartite guidelines: statistical principles for clinical trials. Stats Med. 1999;18:1905–1942. - PubMed
1. Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322:603–606. - PMC - PubMed
1. De Mets DL. Data and safety monitoring boards. In: Redmond C, Colton T, editors. Biostatistics in clinical trials. Wiley: New York; 2000.
1. Pocock S J. When to stop a clinical trial. BMJ. 1992;305:235–240. - PMC - PubMed
1. Fleming T R, De Mets D L. Monitoring of clinical trials: issues and recommendations. Controlled Clin Trials. 1993;14:183–197. - PubMed